Generic of Gilead’s HIV pre-exposure drug coming to market in 2020

A generic version of Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate) will hit the market in 2020, a year earlier than expected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Gilead licenses HIV injections for $25m

24 July 2019 Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

Americas

Gilead hit with antitrust suit over HIV drugs

16 January 2020 Gilead and its alleged co-conspirators Bristol-Myers Squibb, Japan Tobacco, and Johnson & Johnson have been accused of engaging in a long-running scheme to suppress competition in the market for HIV prevention therapies.

Americas

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Americas

Gilead licenses HIV injections for $25m

24 July 2019 Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

Americas

Gilead hit with antitrust suit over HIV drugs

Americas

Gilead accused of illegally paying to delay HIV drug competition

More on this story

Americas

Gilead licenses HIV injections for $25m

24 July 2019 Gilead has obtained exclusive worldwide rights to market a long-acting injectable HIV product based on Durect Corporation’s Saber technology.

Americas

Gilead hit with antitrust suit over HIV drugs

Americas

Gilead accused of illegally paying to delay HIV drug competition